|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.99 USD | -1.44% |
|
-7.63% | -44.67% |
| 04-25 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
| 04-25 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
(Reuters) - Sage Therapeutics said on Thursday it would cut its workforce by about 40%, weeks after the U.S. health regulator declined to approve its drug to treat major depressive disorder.
The U.S. Food and Drug Administration (FDA) in early August approved the company and partner Biogen's pill for postpartum depression, but rejected it as a treatment for major depressive disorder, which is a much larger market.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 226.9 USD | +0.68% | +3.64% | 33.03B | ||
| 11.99 USD | -1.44% | -7.63% | 722M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -44.67% | 722M | |
| +5.33% | 111B | |
| +12.11% | 106B | |
| -12.56% | 22.24B | |
| -3.70% | 21.25B | |
| -6.03% | 18.97B | |
| -35.21% | 18.52B | |
| -10.86% | 16.81B | |
| +5.10% | 13.94B | |
| +37.57% | 12.54B |
SAGE THERAPEUTICS, INC. 
